208 related articles for article (PubMed ID: 15729073)
21. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity.
Hong KP; Shin MH; Yoon S; Ji GY; Moon YR; Lee OJ; Choi SY; Lee YM; Koo JH; Lee HC; Lee GK; Kim SR; Lee KH; Han HS; Choe KH; Lee KM; Hong JM; Kim SW; Yi JH; Ji HJ; Kim YB; Song HG
Biomaterials; 2015 Oct; 67():32-41. PubMed ID: 26204223
[TBL] [Abstract][Full Text] [Related]
23. The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma.
Rose JB; Correa-Gallego C; Li Y; Nelson J; Alseidi A; Helton WS; Allen PJ; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Kowdley KV; Jarnagin WR; Rocha FG
PLoS One; 2016; 11(3):e0150195. PubMed ID: 26974538
[TBL] [Abstract][Full Text] [Related]
24. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.
Pandey R; Zhou M; Islam S; Chen B; Barker NK; Langlais P; Srivastava A; Luo M; Cooke LS; Weterings E; Mahadevan D
Sci Rep; 2019 Dec; 9(1):18347. PubMed ID: 31797958
[TBL] [Abstract][Full Text] [Related]
25. Generation of Rat Monoclonal Antibodies Against Human Pancreatic Ductal Adenocarcinoma Cells.
Higashi K; Fujii N; Kushida M; Yamada K; Suzuki N; Saito K; Tachibana T
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):148-54. PubMed ID: 27172290
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.
Kawanishi A; Hirabayashi K; Yamada M; Takanashi Y; Hadano A; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
J Clin Pathol; 2017 Jul; 70(7):619-624. PubMed ID: 27980052
[TBL] [Abstract][Full Text] [Related]
27. High expression of TROP2 correlates with poor prognosis in pancreatic cancer.
Fong D; Moser P; Krammel C; Gostner JM; Margreiter R; Mitterer M; Gastl G; Spizzo G
Br J Cancer; 2008 Oct; 99(8):1290-5. PubMed ID: 18813308
[TBL] [Abstract][Full Text] [Related]
28. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients.
Hwang IK; Kim H; Lee YS; Kim J; Cho JY; Yoon YS; Han HS; Hwang JH
Cancer Sci; 2015 Oct; 106(10):1408-13. PubMed ID: 26183380
[TBL] [Abstract][Full Text] [Related]
29. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma.
Duxbury MS; Ito H; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 May; 317(3):837-43. PubMed ID: 15081416
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer.
Park S; Kim JW; Kim H; Kim JW; Kim YJ; Lee KW; Kim JH; Kim JH; Hwang JH; Choi YR; Cho JY; Yoon YS; Han HS
APMIS; 2017 Aug; 125(8):699-707. PubMed ID: 28556956
[TBL] [Abstract][Full Text] [Related]
31. Molecular targeting of CEACAM6 using antibody probes of different sizes.
Niu G; Murad YM; Gao H; Hu S; Guo N; Jacobson O; Nguyen TD; Zhang J; Chen X
J Control Release; 2012 Jul; 161(1):18-24. PubMed ID: 22568933
[TBL] [Abstract][Full Text] [Related]
32. CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer.
Roy RK; Hoppe MM; Srivastava S; Samanta A; Sharma N; Tan KT; Yang H; Voon DC; Pang B; Teh M; Murata-Kamiya N; Hatakeyama M; Chang YT; Yong WP; Ito Y; Ho KY; Tan P; Soong R; Koeffler PH; Yeoh KG; Jeyasekharan AD
Oncotarget; 2016 Aug; 7(34):55290-55301. PubMed ID: 27421133
[TBL] [Abstract][Full Text] [Related]
33. Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival.
Matros E; Bailey G; Clancy T; Zinner M; Ashley S; Whang E; Redston M
Cancer; 2006 Feb; 106(3):693-702. PubMed ID: 16362976
[TBL] [Abstract][Full Text] [Related]
34. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer.
Gebauer F; Wicklein D; Horst J; Sundermann P; Maar H; Streichert T; Tachezy M; Izbicki JR; Bockhorn M; Schumacher U
PLoS One; 2014; 9(11):e113023. PubMed ID: 25409014
[TBL] [Abstract][Full Text] [Related]
35. Expression of urocortin in pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia.
Cheng MF; Tsai WC; Hsia KT; Yang YS; Jin JS
APMIS; 2014 Feb; 122(2):147-54. PubMed ID: 23755913
[TBL] [Abstract][Full Text] [Related]
36. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6.
Han HS; Son SM; Yun J; Jo YN; Lee OJ
FEBS Lett; 2014 Oct; 588(20):3744-50. PubMed ID: 25171863
[TBL] [Abstract][Full Text] [Related]
38. Expression and prognostic significance of CEACAM6, ITGB1, and CYR61 in peripheral blood of patients with gastric cancer.
Zhao ZS; Li L; Wang HJ; Wang YY
J Surg Oncol; 2011 Oct; 104(5):525-9. PubMed ID: 21618249
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer.
Lundin J; Nordling S; von Boguslawsky K; Roberts PJ; Haglund C
Anticancer Res; 1995; 15(6B):2659-68. PubMed ID: 8669843
[TBL] [Abstract][Full Text] [Related]
40. c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components.
Duxbury MS; Ito H; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Apr; 317(1):133-41. PubMed ID: 15047158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
